Overview: Donor-Derived cfDNA (dd-cfDNA) TestIntroduction: The Donor-Derived cfDNA Test measures donor-derived cell-free DNA to monitor transplant rejection, preventing organ failure. Aligned with 2023 AST guidelines, it uses PCR for high specificity, aiding in transplant screening. This test is critical for guiding immunosuppressive therapy, monitoring rejection, and improving outcomes in molecular pathology for transplant patients.
Other Names: dd-cfDNA Assay, Transplant Rejection Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: dd-cfDNA testing began in the 2010s with transplant research. PCR-based assays emerged in the 2010s, improving accuracy for rejection monitoring.
Purpose: Monitors transplant rejection, guides immunosuppressive therapy, and detects donor DNA in patients at risk of organ failure.
Test Parameters: 1. Donor-Derived Cell-Free DNA
Pretest Condition: No fasting required. Collect whole blood or plasma at any time. Report symptoms like fatigue or organ dysfunction, and list immunosuppressive medications.
Specimen: 2-5 mL whole blood (EDTA) or 2-4 mL plasma (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document transplant history, organ dysfunction, or symptoms like fatigue. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, implications for transplant monitoring, and potential need for therapy adjustments.
Procedural Considerations: Uses PCR to quantify donor-derived cfDNA. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Contamination or low DNA yield can affect results. Improper storage may reduce sensitivity.
Clinical Significance: Elevated dd-cfDNA levels suggest transplant rejection, prompting therapy adjustments. Normal levels support stable graft function.
Specialist Consultation: Consult a transplant specialist for result interpretation.
Additional Supporting Tests: Biopsy, kidney/liver function tests, or imaging to confirm rejection.
Test Limitations: Results may be affected by non-rejection factors (e.g., infection). Clinical correlation is required.
References: AST Transplant Guidelines, 2023; American Journal of Transplantation, Bloom RD, 2022.
